Early trial tests cell therapy to reboot immune system against cancer
NCT ID NCT03096093
Summary
This early-stage study is testing a new cell-based immunotherapy called ACIT-1 in adults with cancer. The main goals are to find the safest dose and see if the treatment can help the patient's own immune system recognize and attack cancer cells. About half of the participants will have pancreatic cancer, while the other half will have other types of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8XP, United Kingdom
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, CH63 4JY, United Kingdom
Conditions
Explore the condition pages connected to this study.